Synthesis and Crystal Structure of 3,3′-(Hexane-1,6-diyl)bis(1-acetyl-5,5-dimethylhydantoin),a New Inducer of Differentiation

1 INTRODUCTION Hexamethylenebis[acetamide] (HMBA) is an effective agent in phaseⅡclinical trial[1] that induces differentiation of certain types of tumors to nonmalignant phenotypes. In an attempt to discover more efficient inducers, a number of derivatives of HMBA have been synthesized and evaluated in vitro[2, 3]. The results proved that increasing the number of functional groups could enhance the anticancer activity. In addition, it was evident that compounds with six methylene i…     

Synthesis and Crystal Structure of 3,3‘—（Hexane—1,6—diyl）bis（1—acetyl—5,5—dimethylhydantoin）,a New Inducer of Differentiation

The title compound C20H30N4O6, Mr = 422.48)was synthesized and its crystal structure was determined by X-ray diffraction method. It crystallizes in the triclinic system, space group P ī with cell parameters: a = 8.330(2), b = 8.468(2), c = 16.017(3) A, α = 97.30(3), β = 92.33(3), γ = 103.94(3)o, V = 1084.7(4) A3, Dc = 1.294 g/cm3, Z = 2, F(000) = 452 and μ = 0.096 mm-1. The structure was refined to R = 0.0483 for 3732 observed reflections with I>2(I) and wR = 0.1335 for 4828 unique reflections. The hydantoin rings are planar and the two ring planes of one molecule are paralleled to each other.     

Direct injection analysis of hexamethylene bisacetamide in biological fluids by an HPLC column switching technique with a micellar mobile phase

Summary This paper describes the direct injection analysis of the anti-cancer drug hexamethylene bisacetamide (HMBA) in biological fluids by an HPLC column switching technique. The first chromatographic column, which provides for sample extraction and cleanup, employs a micellar mobile phase with SDS as the modifier. The second column, coupled on-line to the first, utilizes reversed-phase conditions for analysis. UV detection is employed at 210 nm. 282 samples from 12 cancer patients were analysed and good pharmacokinetics curves obtained. The drug gives recoveries of 94.0–100.9% with a relative standard deviation of 1.88%. A sample analysis is completed within 15 minutes. This method should be satisfactory not only for the analysis of HMBA but also, probably for other drugs in biological fluids.     

Gas Chromatographic Determination of Hexamethylene Bisacetamide in Plasma and Urine

Abstract

A rapid, simple and specific gas chromatographic method has been developed to measure the differentiating agent hexamethylene bisacetamide (HMBA) in biological samples. Addition of a homolog as an internal standard, ultrafiltration and then direct packed column GC-FID analysis of the ultrafiltrate gives a detection limit of less than 50 μg/ml (0.25 mM) for HMBA in plasma or urine. Ultrafiltration is quantitative and assay precision is better than 4.3% for the 1–5 mM range. This method has been applied to determine the bolus dose pharmacokinetics and disposition of HMBA in a single small animal such as a rat. The developed assay should be suitable for therapeutic monitoring of human patients undergoing HMBA treatment.     

环糊精与抗癌药物HMBA相互作用的谱学研究

α－,β－,γ－ＣＤ与抗癌药ＨＭＢＡ相互作用的ＮＭＲ研究表明ＨＭＢＡ分子大小与α－ＣＤ内腔尺寸最为匹配,相互作用力最强。１３Ｃ－ＮＭＲ研究表明α－ＣＤ与ＨＭＢＡ形成了包结物,而且两者之间还有氢键存在。ＨＭＢＡ上的α－Ｃ,在与α－ＣＤ作用后产生的较大低场位移,说明在ＨＭＢＡ·α－ＣＤ体系中包结作用较强,使ＨＭＢＡ上α－Ｃ化学位移变化大。而ＨＭＢＡ上的－Ｃ＝Ｏ,在与α－,β－ＣＤ作用后产生高场位移,位移程度ＨＭ－ＢＡ．β－ＣＤ＞ＨＭＢＡ．α－ＣＤ,则氢键作用在ＨＭＢＡ．β－ＣＤ体系中较强些。     

N-terminus FITC labeling of peptides on solid support: the truth behind the spacer

Fluorescein isothiocyanate (FITC) is an amine reactive derivative of fluorescein dye that has wide ranging application in biochemistry. It has been extensively used to label peptides and proteins. However, its use in solid phase peptide synthesis is restricted. Indeed, in acidic conditions required for linker cleavage, N-ter FITC-labeled peptides undergo a cyclization leading to the formation of a fluorescein with subsequent removal of the last amino acid. This can be avoided when a spacer such as amino hexanoic acid is used or if non-acidic cleavage is operated to release targeted peptide from the resin.     

分化诱导剂PMDH的合成及晶体结构

合成了分化诱导剂1,5-二[3,3’-5,5-二甲基乙内酰脲]]戊烷(PMDH), 对合成方法和路线进行了优化，并通过元素分析、质谱、核磁和红外进行了表征. 利用单晶X射线衍射仪测定了化合物的晶体结构，晶体属于三斜晶系，空间群为P1, 晶体学参数为: a =0.874 1(4) nm, b =1.114 6(2) nm, c =1.721 0(3) nm, α= 87.20(3)°,β= 89.77(3) °, γ=85.12(3)°， V= 1.668 6(6) nm3 ，Z=4.最终偏离因子R1= 0.0651.分子中的碳链连接两个乙内酰脲五元环，五元环与和它相连的两个羰基氧原子呈平面结构, 分子间存在较强的氢键.     

分化诱导剂的合成及晶体结构

合成出四个分化诱导剂,N,N,N',N'-四乙酰已二胺(Ⅰ),1,6-二烟酰已二胺(Ⅱ),1,6-二(3,5-二氧哌嗪)已烷(Ⅲ)和1,6-二[3,3'-(5,5-二甲乙内酰脲)]已烷(Ⅳ),对合成方法和路线进行了优化,通过元素分析、质谱、核磁和红外进行了表征,测定了化合物Ⅲ对人白血病细胞的分化诱导活性,利用单晶X射线四圆衍射测定了化合物Ⅳ的晶体结构,并与化合物Ⅰ,Ⅱ,Ⅲ的晶体结构进行了比较。     

Synthesis and characterization of a UV absorbent-intercalated Zn-Al layered double hydroxide

Zn-Al-layered double hydroxides (LDHs) containing the organic anion of 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid (HMBA), a highly efficient UV absorber, have been synthesized by reaction in air of HMBA with an LDH-carbonate precursor obtained by a process involving separate nucleation and aging steps. The structural properties, photo- and thermal stability of the resulting Zn-Al-HMBA-LDHs were characterized by PXRD, FT-IR and UV-visible spectroscopy and laser particle-size analysis. The results obtained indicated that Zn-Al-HMBA-LDHs synthesized by this method were relatively highly crystalline and had a narrow distribution of particle size. Intercalation of HMBA in the LDH interlayer galleries resulted in an enhanced photo- and thermal stability without affecting its UV absorption capacity; this shows that the hybrid HMBA-LDH phase has potential applications as a UV absorber.     

胶束多维高效液相色谱法直接进样测定血浆/尿中抗癌药物HMBA

采用两根反相柱串联的多维HPLC,直接进样测定血浆/尿中抗癌药物六亚甲基二乙酰胺(HMBA)。第一根柱使用胶束流动相,作为样品的纯化和富集步骤,第二根柱为分析柱。紫外检测波长为210 nm。药物的回收率在94.0～100.9%之间,相对标准偏差为1.88%。用该法对十二位不同恶性肿瘤患者的282个血浆/尿样品进行了测定,得到了满意的结果并建立了药代动力学曲线。